Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 1,001,578 shares at $23.14 ($22.7M) on 2024-02-21, disclosed to the SEC on 2024-02-23.
Scheduled sale ($22.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.44 | 149,337 | $3.4M | 14.8% |
| 2 | $22.44 | 149,337 | $3.4M | 14.8% |
| 3 | $23.14 | 35,164 | $814K | 3.6% |
| 4 | $23.14 | 35,164 | $814K | 3.6% |
| 5 | $22.66 | 119,360 | $2.7M | 11.9% |
| 6 | $22.66 | 119,360 |
| $2.7M |
| 11.9% |
| 7 | $22.70 | 159,542 | $3.6M | 16.0% |
| 8 | $22.70 | 13,738 | $312K | 1.4% |
| 9 | $22.70 | 13,738 | $312K | 1.4% |
| 10 | $22.70 | 23,648 | $537K | 2.4% |
| 11 | $22.70 | 23,648 | $537K | 2.4% |
| 12 | $22.70 | 159,542 | $3.6M | 16.0% |
| Total | $22.64 avg | 1,001,578 | $22.7M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |